

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業

Mabpharm Limited

迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2181)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF CLINICAL TRIAL APPLICATION OF CMAB807X BY
THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA

This announcement is made by Mabpharm Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the National Medical Products Administration of China (the “**NMPA**”) has approved the clinical trial application of CMAB807X for treatment of tumor bone metastasis.

CMAB807X (Denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand), which is a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. CMAB807 prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bones. CMAB807 is currently under phase III clinical trials for osteoporosis. CMAB807X is a dosage form of CMAB807 for the treatment of tumor bone metastasis. It is expected that CMAB807X can be used for treatment of tumor bone metastasis and giant bone cell tumor and prevent skeletal-related events in patients with solid tumor bone metastases and multiple myeloma after its new drug application is approved by the NMPA.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain approval, develop or ultimately market, CMAB807X successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, January 13, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Dr. Liu Linqing as independent non-executive Directors.